Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation · 2012
Allografts positive for hepatitis B surface antigen in liver transplant for disease related to hepatitis B virus.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ju Weiqiang, Chen Maogen, Guo Zhiyong, Wang Dongping, Zhu Xiaofeng, Huang Jiefu, He Xiaoshun
Аннотация
OBJECTIVES: Liver grafts from hepatitis B surface antigen-negative and anti-core antibody-positive donors are safe for liver transplant. However, the use of hepatitis B surface antigen-positive liver donors in liver transplants is controversial. We assessed the safety and effectiveness of liver transplants using hepatitis B surface antigen-positive liver grafts to patients with diseases related to hepatitis B virus.
MATERIALS AND METHODS: We retrospectively reviewed 23 patients who had a deceased-donor liver transplant using hepatitis B surface antigen-positive liver grafts. All patients had end-stage liver disease secondary to hepatitis B virus infection. Recipients had oral entecavir and intravenous or intramuscular injection of hepatitis B immune globulin for >1 year after the transplant.
RESULTS: Two patients died from severe perioperative pneumonia, and the other 21 patients were followed for 9 to 38 months after transplant. All 21 patients remained hepatitis B surface antigen-positive. A repeat liver transplant was performed in 1 patient at 5 months after the initial transplant because of biliary ischemia. There were 3 patients who died from recurrent liver cancer at 9, 14, and 18 months after transplant. There were 18 patients (78%) who survived and 17 grafts (74%) that survived.
CONCLUSIONS: Liver transplant using hepatitis B surface antigen-positive liver grafts is safe for patients with end-stage liver disease secondary to hepatitis B virus infection.
MATERIALS AND METHODS: We retrospectively reviewed 23 patients who had a deceased-donor liver transplant using hepatitis B surface antigen-positive liver grafts. All patients had end-stage liver disease secondary to hepatitis B virus infection. Recipients had oral entecavir and intravenous or intramuscular injection of hepatitis B immune globulin for >1 year after the transplant.
RESULTS: Two patients died from severe perioperative pneumonia, and the other 21 patients were followed for 9 to 38 months after transplant. All 21 patients remained hepatitis B surface antigen-positive. A repeat liver transplant was performed in 1 patient at 5 months after the initial transplant because of biliary ischemia. There were 3 patients who died from recurrent liver cancer at 9, 14, and 18 months after transplant. There were 18 patients (78%) who survived and 17 grafts (74%) that survived.
CONCLUSIONS: Liver transplant using hepatitis B surface antigen-positive liver grafts is safe for patients with end-stage liver disease secondary to hepatitis B virus infection.
Предметные рубрики MeSH
Administration, OralAdultAntiviral AgentsBiomarkersCarcinoma, HepatocellularDonor SelectionDrug Administration ScheduleGuanineHepatitis BHepatitis B Surface AntigensHepatitis B VaccinesHumansImmunosuppressive AgentsInjections, IntramuscularInjections, IntravenousKaplan-Meier EstimateLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedRetrospective StudiesRisk FactorsTime FactorsTissue DonorsTreatment Outcome